Extended Maintenance with Imatinib Enhances Disease-Free Survival in High-Risk GIST.

Published Date: 13 May 2024

DFS after three years was 87% after six years as opposed to 55% after three, but the toxicity was higher.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Exercise can counter detrimental effects of cancer treatment, review suggests

2.

Another KRAS Inhibitor Scores an Early Win in Advanced Non-Small Cell Lung Cancer

3.

New research points out a promising strategy for treating metastatic medulloblastoma

4.

On all CAR-T products, the FDA is calling for a new boxed warning.

5.

Congress Ditched Fix to Medicare Doc Pay Cut in Skinny Budget Bill


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot